This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William J. Weiner, MD; Paul A. Nausieda, MD
Department of Neurological Sciences Rush-Presbyterian-St Luke's Medical Center 1753 W Congress Pkwy Chicago, IL 60612

Arch Neurol. 1981;38(8):534.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The recent report by Tourtellotte et al (ARCHIVES 1980; 37:723-726) describing their study of the use of an increased ratio of carbidopa to levodopa in the treatment of Parkinson's disease is rather difficult to interpret. The authors used an investigational design that allowed them to study three separate groups of patients with Parkinson's disease who had ceased receiving levodopa or carbidopa-levodopa (10:100) for at least one month. These groups of patients were treated with either levodopa, carbidopa-levodopa (10:100), or carbidopa-levodopa (20:100), and their degree of parkinsonian disability was evaluated. The response of the patients to these three different treatment regimens after a two-week period was used to conclude that increasing the amount of carbidopa in presently available drugs is a desirable treatment modality.

Although the authors do state that their study "was conducted over a relatively short period," Parkinson's disease, in particular the therapy of Parkinson's disease . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?